Use of ribose in first response to acute myocardial infarction
AssigneeBioenergy Life Science, Inc.
InventorsJohn A. St. Cyr, David J. Perkowski
Life of this patent
Estimating the term…
Abstract
D-ribose is administered to patients suffering an acute myocardial infarction during first response care, in order to prevent cardiac compromise. In those patients able to ingest fluids, two to five grams of D-ribose is administered orally. In a patients unable to ingest fluids, or in a patient with and intravenous line, pyrogen-free D-ribose is administered intravenously at a rate of 50-300 mg/kg/hour.
Claims2
A method comprising the administration of an effective amount of D-ribose to a patient suffering from acute myocardial infarction wherein the patient's cardiac index is maintained or improved.
2-6. (canceled)
Dependencies are inferred from the claim text.